Eagle Pharmaceutical (EGRX) 60.34 $EGRX Chemica
Post# of 273257
Posted On: 09/03/2016 11:24:50 PM
Eagle Pharmaceutical (EGRX) 60.34 $EGRX
Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Mon Aug 22, 4:51PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
SPGI: 125.43 (+1.49), TLMR: 23.26 (-0.44), SVU: 5.72 (+0.21), SCVL: 26.17 (-0.01), FCFS: 52.83 (+2.51), SGNT: 21.76 (+0.03), EGRX: 60.34 (+1.32), CHFC: 44.36 (-0.65), CSH: 42.20 (-1.33)
InvestorsObserver releases covered-call reports for Netflix, Nevro Corporation, Eagle Pharmaceuticals, Mylan and Weibo
PR Newswire - Wed Aug 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EGRX, MYL, NFLX, NVRO, and WB.
NFLX: 97.38 (unch), WB: 49.54 (+0.52), MYL: 39.97 (-1.95), EGRX: 60.34 (+1.32), NVRO: 95.91 (-0.11)
Eagle Pharmaceuticals (EGRX) Soars: Stock Moves 14.6% Higher
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:00AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise over 14% on the day
LNTH: 9.40 (-0.10), EGRX: 60.34 (+1.32)
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
BusinessWire - Tue Aug 09, 5:50AM CDT
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"
(Nasdaq:EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include:
EGRX: 60.34 (+1.32)
Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission
BusinessWire - Tue Aug 09, 5:45AM CDT
-- Hybrid Rule (Human and Animal Data) Reaffirmed --
EGRX: 60.34 (+1.32)
Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 12.52 (+0.05), STE: 71.00 (+0.89), EGRX: 60.34 (+1.32), PEN: 70.63 (+0.61), OMER: 11.10 (+0.34)
SHAREHOLDER ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important August 1 Deadline in Class Action - EGRX
GlobeNewswire - Mon Aug 01, 6:00PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period" of the important August 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws.
EGRX: 60.34 (+1.32)
EGRX Investors: The Wagner Firm Announces The Filing Of A Securities Class Action On Behalf of Eagle Pharmaceuticals Inc. Investors
BusinessWire - Mon Aug 01, 12:40PM CDT
The Wagner Firm announces the filing of a class action lawsuit on behalf of investors who purchased Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) securities between February 23, 2016 and March 18, 2016, inclusive (the "Class Period". Eagle investors have until August 1, 2016 to file a lead plaintiff motion.
EGRX: 60.34 (+1.32)
3-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Fri Jul 29, 10:59AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 29, 2016 / Lundin Law PC (the "Firm" announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.
EGRX: 60.34 (+1.32)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 29, 8:27AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company" (Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period", are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline.
EGRX: 60.34 (+1.32)
INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws.
EGRX: 60.34 (+1.32)
EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 60.34 (+1.32)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.74 (+0.06), HCP: 39.08 (+0.28), UNIS: 2.79 (+0.01), CBL: 13.65 (+0.05), INFI: 1.56 (+0.04), EGRX: 60.34 (+1.32), NVCN: 0.58 (+0.01)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 36.98 (-0.02), CBL: 13.65 (+0.05), TRXC: 1.39 (+0.02), EGRX: 60.34 (+1.32), NVCN: 0.58 (+0.01)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company" (NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
EGRX: 60.34 (+1.32)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Mon Aug 22, 4:51PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
SPGI: 125.43 (+1.49), TLMR: 23.26 (-0.44), SVU: 5.72 (+0.21), SCVL: 26.17 (-0.01), FCFS: 52.83 (+2.51), SGNT: 21.76 (+0.03), EGRX: 60.34 (+1.32), CHFC: 44.36 (-0.65), CSH: 42.20 (-1.33)
InvestorsObserver releases covered-call reports for Netflix, Nevro Corporation, Eagle Pharmaceuticals, Mylan and Weibo
PR Newswire - Wed Aug 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EGRX, MYL, NFLX, NVRO, and WB.
NFLX: 97.38 (unch), WB: 49.54 (+0.52), MYL: 39.97 (-1.95), EGRX: 60.34 (+1.32), NVRO: 95.91 (-0.11)
Eagle Pharmaceuticals (EGRX) Soars: Stock Moves 14.6% Higher
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:00AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise over 14% on the day
LNTH: 9.40 (-0.10), EGRX: 60.34 (+1.32)
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
BusinessWire - Tue Aug 09, 5:50AM CDT
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"
(Nasdaq:EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include: EGRX: 60.34 (+1.32)
Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission
BusinessWire - Tue Aug 09, 5:45AM CDT
-- Hybrid Rule (Human and Animal Data) Reaffirmed --
EGRX: 60.34 (+1.32)
Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 12.52 (+0.05), STE: 71.00 (+0.89), EGRX: 60.34 (+1.32), PEN: 70.63 (+0.61), OMER: 11.10 (+0.34)
SHAREHOLDER ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important August 1 Deadline in Class Action - EGRX
GlobeNewswire - Mon Aug 01, 6:00PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period"
of the important August 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws. EGRX: 60.34 (+1.32)
EGRX Investors: The Wagner Firm Announces The Filing Of A Securities Class Action On Behalf of Eagle Pharmaceuticals Inc. Investors
BusinessWire - Mon Aug 01, 12:40PM CDT
The Wagner Firm announces the filing of a class action lawsuit on behalf of investors who purchased Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"
(NASDAQ: EGRX) securities between February 23, 2016 and March 18, 2016, inclusive (the "Class Period". Eagle investors have until August 1, 2016 to file a lead plaintiff motion. EGRX: 60.34 (+1.32)
3-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Fri Jul 29, 10:59AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 29, 2016 / Lundin Law PC (the "Firm"
announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline. EGRX: 60.34 (+1.32)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 29, 8:27AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"
(Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period", are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline. EGRX: 60.34 (+1.32)
INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"
(NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws. EGRX: 60.34 (+1.32)
EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 60.34 (+1.32)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.74 (+0.06), HCP: 39.08 (+0.28), UNIS: 2.79 (+0.01), CBL: 13.65 (+0.05), INFI: 1.56 (+0.04), EGRX: 60.34 (+1.32), NVCN: 0.58 (+0.01)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 36.98 (-0.02), CBL: 13.65 (+0.05), TRXC: 1.39 (+0.02), EGRX: 60.34 (+1.32), NVCN: 0.58 (+0.01)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"
(NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act". EGRX: 60.34 (+1.32)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 60.34 (+1.32)
(0)
(0)Scroll down for more posts ▼